Better Health for All

Coloplast's core business, including ostomy, continence, wound care, and interventional urology products, is dedicated to improving the lives of people with intimate healthcare needs.

The Coloplast Care program has demonstrated significant positive health outcomes, including a 47% decrease in emergency department visits and a 77% reduction in overnight hospital admissions for intermittent catheter users. The company has no revenue from products with inherent negative health outcomes. However, Coloplast has faced significant safety challenges, with 4 voluntary product recalls in 2020/21, a recall of 9 units of Titan Pump Assembly in March 2023 due to potential premature pump failure, and a recall of 36,369 units of X-Flow prostatectomy catheters in December 2024 due to a possible sterility issue, totaling more than 5 recalls in the past three years. The company supported over two million users across 140 countries in 2024/25 and welcomed over 260,000 new participants to patient support programs. Coloplast invests in healthcare innovation and plans significant investments in new technology platforms. The company has an Ethics Hotline for anonymous reporting of concerns and is working to be transparent about data usage. Coloplast provides sponsorships and educational grants to healthcare professionals and conducts clinical trials in accordance with regulatory requirements. The company's DE&I policy aims for a diverse workplace, with a Board of Directors having a 50/50 gender split and a target of 40/60 gender representation by 2030. Emotional support is a key component of the Coloplast Care program.

Fair Money & Economic Opportunity

Coloplast A/S is a medical device company.

The 'Fair Money & Economic Opportunity' value primarily assesses financial institutions and their impact on financial inclusion. The provided articles describe Coloplast's operations related to medical devices, healthcare access, internal diversity, and data ethics concerning patient data. There is no evidence that the company offers lending, deposit services, insurance, or other financial products to consumers or businesses. Therefore, none of the KPIs in the rubric, which are designed for financial services, can be scored based on the available information.

Fair Pay & Worker Respect

No specific, company-wide quantitative data is available across the provided articles to assess Coloplast A/S (CBHD.XETRA) against the Fair Pay & Worker Respect KPIs. While some articles provide data for 'Coloplast, Inc.' (a US entity) or 'COLOPLAST LIMITED' (a UK entity), this information is specific to subsidiaries and does not explicitly state company-wide scope.

Therefore, it cannot be applied to the entire multinational company being assessed.

Honest & Fair Business

Coloplast incurred a $14.5 million ethics-related regulatory fine in 2022.

The company had one financial restatement in FY 2023/24, adjusting emissions data from 27% to 22%. Four out of six shareholder-elected board members are considered independent, which is 66.7% of the shareholder-elected board. Coloplast has a Global Speak Up and Anti-Retaliation Policy, an externally operated Ethics Hotline allowing anonymous reporting, and reported 61 total cases in FY 2020/21, with 25 via the hotline. 99% of white-collar employees received Code of Conduct training in FY 2020/21. The company has a Global Anti-Bribery and Corruption Policy, prohibits bribery, and trains employees in its code of conduct, including specific guidelines on payments and gifts. Coloplast's products and processes undergo frequent external auditing by independent auditors and notified bodies, and it voluntarily participates in selected ESG ratings to provide third-party verified insights.

Kind to Animals

Coloplast reported using 1,068 animals for tests in 2024/25, with 87% being rodents.

This is a decrease from 1,576 animals in 2020/21 but an increase from 217 animals in 2010/11. The company has a global animal testing policy, finalized in February 2024, which adheres to the 'three R's' (Replacement, Refinement, and Reduction) and is reviewed annually. They state they cannot completely avoid animal testing due to regulatory requirements, but they challenge the need for testing and use methods causing the least distress. Coloplast employs alternative testing methods such as chemical characterization, cell cultures, and computer modelling. The company states it regularly monitors suppliers for compliance with animal welfare standards and retains audit rights where specified in contracts, but no percentage of suppliers audited for welfare compliance is provided. Coloplast's R&D costs amounted to 3% of revenue in 2024/25, but there is no specific percentage of this budget allocated to animal-free technologies.

Planet-Friendly Business

Coloplast's total Scope 1, 2, and 3 emissions were 223,300 tCO2e in 2024, which represents a 1.91% increase from 219,100 tCO2e in 2023.

The company's carbon reduction targets are validated by the Science Based Targets initiative (SBTi) for a 1.5°C pathway, committing to a 100% reduction in absolute Scope 1 and 2 GHG emissions by 2030 and a 50% reduction in Scope 3 GHG emissions per product by 2030, both from a 2018/2019 base year. In 2024/25, 69% of total energy consumption was from renewable sources. Production waste recycling reached 83% in FY 2024/25, exceeding the 2025 ambition of 75%. The company concluded it has no material eligible activities to report under the EU Taxonomy Regulation. A sustainability assessment process is defined for innovation projects in chronic care and wound and skin care, with plans to expand to other areas in 2022/23. Coloplast has a net-zero target year of 2045. The company is committed to reporting according to TCFD recommendations and plans to initiate a climate scenario analysis in 2025/26. Coloplast engages with its top-emitting suppliers, expanding from 50 in 2021/22 to over 100, as part of its Supplier Sustainability Programme.

Respect for Cultures & Communities

Coloplast's Access to Healthcare program has supported over 100 projects in 25 countries since 2007, collaborating with local stakeholders to create value for people with intimate healthcare needs.

The company has not reported any cultural appropriation incidents. The Code of Conduct (Coloplast BEST) is available in 16 languages, and the Ethics Hotline is accessible in all languages spoken in the countries where Coloplast operates. In 2023/24, 99% of white-collar employees completed Code of Conduct training, but this is not specified as cultural sensitivity training.

Safe & Smart Tech

Coloplast has not reported any data breaches in the provided articles, and has established a Data Protection Breach Procedure for immediate reporting to authorities within 72 hours and data subjects without undue delay if there is a high risk.

The company adopted a Data & AI Ethics Policy, approved by the Board of Directors on November 3, 2025, which includes overarching principles, executive leadership responsibility, reporting structures, and annual review. It prohibits automated decisions with legal consequences or substantial prejudice for data subjects. Coloplast holds ISO 27001 certification for its information security management system and has Binding Corporate Rules (BCR) in place. The company provides targeted awareness training to all employee categories, and 99% of white-collar employees completed Code of Conduct training in 2023. Transmission of personal data within the company's own network is typically encrypted, to the extent required by its nature and purpose. Coloplast conducts data protection impact assessments for high-risk processing activities and consults with data protection authorities if high risks remain. The company strives to clearly explain when and how AI is used, including how personal data is handled and its potential impact. Coloplast only collects, uses, discloses, or stores personal data for specific, legitimate, and necessary purposes. Users have rights to access, correct, and request deletion of their personal information, and can opt-out of the sale or sharing of personal information. All computers and mobile devices are password/passcode protected and managed through a device management tool. Coloplast conducts external vulnerability and penetration tests and focuses on transparency and control for faster threat response. The company integrates 'data protection by design' and 'data protection by default' principles into its processes. Data is retained only as long as needed for its purpose, with specific retention periods such as up to ten years after the last product delivery. Coloplast states compliance with GDPR and other applicable data protection laws. The company strives to reduce negative impacts of AI and improve effectiveness, safety, quality, and value for users.

Zero Waste & Sustainable Products

Coloplast recycled 58% of its production waste in 2020/21, exceeding its 2025 target of 50%.

The company has set a new target to achieve 75% waste recycling by 2025. Coloplast has reduced waste generated per product for four consecutive years, attributed to new production technologies and product design improvements. The company runs campaigns through its Coloplast Care program to educate users on proper recycling, and its Heylo packaging eliminates plastics using FSC™ certified cardboard.